SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-006383
Filing Date
2022-04-27
Accepted
2022-04-27 16:21:10
Documents
12
Period of Report
2022-04-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K virx-20220425.htm   iXBRL 8-K 47646
  Complete submission text file 0000950170-22-006383.txt   161013

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT virx-20220425_pre.xml EX-101.PRE 9535
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT virx-20220425.xsd EX-101.SCH 2480
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT virx-20220425_lab.xml EX-101.LAB 12890
6 EXTRACTED XBRL INSTANCE DOCUMENT virx-20220425_htm.xml XML 4545
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51531 | Film No.: 22859909
SIC: 2834 Pharmaceutical Preparations